Professor Kristensen said: “Overall there is improvement since the last survey but there is still quite a lot of work to do in several countries. PPCI is the best therapy but if it isn’t available then thrombolysis is an acceptable option. The worst case scenario is when patients do not get any reperfusion therapy.”
Professor Kristensen concluded: “PPCI is the first choice of treatment in most countries but more work is needed to ensure equal access for all patients. The SFL Initiative will continue to help countries identify their own barriers to implementing guidelines (e.g. poor access to emergency health services, economic factors or lack of trained doctors) and find ways of increasing their use of life saving PPCI.”
Stent for Life (SFL) is an initiative of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), a registered branch of the ESC and EuroPCR. SFL aims to improve the delivery of care and patient access to the life saving indications of primary percutaneous coronary intervention (PPCI), thereby reducing mortality and morbidity in patients suffering from acute coronary syndromes. See www.stentforlife.com for more information and a list of participating countries.
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved